Journal ArticleDOI
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik,Steven Shak,Gong Tang,Chungyeul Kim,Joffre B. Baker,Maureen T. Cronin,Frederick L. Baehner,Michael G. Walker,Drew Watson,Taesung Park,William Hiller,Edwin R. Fisher,D. Lawrence Wickerham,John Bryant,Norman Wolmark +14 more
Reads0
Chats0
TLDR
The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.Abstract:
background The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor–positive tumors is poorly defined by clinical and histopathological measures. methods We tested whether the results of a reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancerrelated genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient. results Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan–Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P<0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P<0.001). The recurrence score was also predictive of overall survival (P<0.001) and could be used as a continuous function to predict distant recurrence in individual patients. conclusions The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor–positive breast cancer.read more
Citations
More filters
Journal ArticleDOI
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Richard Buus,Ivana Sestak,Ralf Kronenwett,Carsten Denkert,P Dubsky,Kristin Krappmann,Marsel Scheer,Christoph Petry,Jack Cuzick,Mitch Dowsett +9 more
TL;DR: EP and EPclin were highly prognostic for DR in endocrine-treated patients with ER+, HER2-negative disease, partly but not entirely because of EP clin integrating molecular data with nodal status and tumor size.
Journal ArticleDOI
Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer
Marieke E. Straver,P. Meijnen,Geertjan van Tienhoven,Cornelis J.H. van de Velde,Robert E. Mansel,Jan Bogaerts,Gaston Demonty,Nicole Duez,Luigi Cataliotti,Jean H. G. Klinkenbijl,Helen A. Westenberg,Hueb van der Mijle,Coen W. Hurkmans,Emeil J. T. Rutgers +13 more
TL;DR: The AMAROS trial as discussed by the authors compared axillary lymph node dissection (ALND) and axillary radiation therapy (ART) in early breast cancer patients with tumor-positive sentinel nodes.
Journal ArticleDOI
MYC regulation of a "poor-prognosis" metastatic cancer cell state
Anita Wolfer,Ben S. Wittner,Daniel Irimia,Richard Flavin,Mathieu Lupien,Ruwanthi N. Gunawardane,Clifford A. Meyer,Eric S. Lightcap,Pablo Tamayo,Jill P. Mesirov,X. Shirley Liu,Toshi Shioda,Mehmet Toner,Massimo Loda,Myles Brown,Joan S. Brugge,Sridhar Ramaswamy +16 more
TL;DR: It is found that the c-MYC oncoprotein coordinately regulates the expression of 13 different “poor-outcome” cancer signatures and functional inactivation of MYC in human breast cancer cells specifically inhibits distant metastasis in vivo and invasive behavior in vitro of these cells.
Journal ArticleDOI
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Srikanth Nagalla,Jeff W. Chou,Mark C. Willingham,Jimmy Ruiz,James P. Vaughn,Purnima Dubey,Timothy L. Lash,Timothy L. Lash,Stephen Hamilton-Dutoit,Jonas Bergh,Jonas Bergh,Christos Sotiriou,Michael A. Black,Lance D. Miller +13 more
TL;DR: It is suggested that a productive interplay among multiple immune cell types at the tumor site promotes long-term anti-metastatic immunity in a proliferation-dependent manner and the emergence of a subset of effective immune responders among highly proliferative tumors has novel prognostic ramifications.
Journal ArticleDOI
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
Dennis C. Sgroi,Erin Carney,Elizabeth Zarrella,Lauren Steffel,Shemeica Binns,Dianne M. Finkelstein,Jackie Szymonifka,Atul K. Bhan,Lois E. Shepherd,Yi Zhang,Catherine A. Schnabel,Mark G. Erlander,James N. Ingle,Peggy L. Porter,Hyman B. Muss,Katherine I. Pritchard,Katherine I. Pritchard,Dongsheng Tu,David L. Rimm,Paul E. Goss +19 more
TL;DR: In the absence of extended letrozole therapy, high H/I identifies a subgroup of ER-positive patients disease-free after 5 years of tamoxifen who are at risk for late recurrence.
References
More filters
Journal ArticleDOI
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
Todd R. Golub,Todd R. Golub,Donna K. Slonim,Pablo Tamayo,Christine Huard,Michelle Gaasenbeek,Jill P. Mesirov,Hilary A. Coller,Mignon L. Loh,James R. Downing,Michael A. Caligiuri,Clara D. Bloomfield,Eric S. Lander +12 more
TL;DR: A generic approach to cancer classification based on gene expression monitoring by DNA microarrays is described and applied to human acute leukemias as a test case and suggests a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge.
Journal ArticleDOI
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Therese Sørlie,Charles M. Perou,Robert Tibshirani,Turid Aas,Stephanie Geisler,Hilde Johnsen,Trevor Hastie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,T. Thorsen,Hanne Quist,John C. Matese,Patrick O. Brown,David Botstein,Per Eystein Lønning,Anne Lise Børresen-Dale +16 more
TL;DR: Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Journal ArticleDOI
Quantitative monitoring of gene expression patterns with a complementary DNA microarray.
TL;DR: A high-capacity system was developed to monitor the expression of many genes in parallel by means of simultaneous, two-color fluorescence hybridization, which enabled detection of rare transcripts in probe mixtures derived from 2 micrograms of total cellular messenger RNA.
Journal ArticleDOI
Gene expression profiling predicts clinical outcome of breast cancer
Laura J. van't Veer,Hongyue Dai,Marc J. van de Vijver,Yudong D. He,Augustinus A. M. Hart,Mao Mao,Hans Peterse,Karin van der Kooy,Matthew J. Marton,Anke T. Witteveen,George J. Schreiber,Ron M. Kerkhoven,Christopher J. Roberts,Peter S. Linsley,René Bernards,Stephen H. Friend +15 more
TL;DR: DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.
Related Papers (5)
Gene expression profiling predicts clinical outcome of breast cancer
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver,Yudong D. He,Laura J. van't Veer,Hongyue Dai,Augustinus A. M. Hart,D.W. Voskuil,George J. Schreiber,Johannes L. Peterse,Christopher J. Roberts,Matthew J. Marton,Mark Parrish,Douwe Atsma,Anke T. Witteveen,Annuska M. Glas,Leonie J. M. J. Delahaye,Tony van de Velde,Harry Bartelink,Sjoerd Rodenhuis,Emiel J. Th. Rutgers,Stephen H. Friend,René Bernards +20 more
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more